The Experts below are selected from a list of 291 Experts worldwide ranked by ideXlab platform
Manuel Casal - One of the best experts on this subject based on the ideXlab platform.
-
In Vitro Activity of Voriconazole against Prototheca Wickerhamii: Comparative Evaluation of Sensititre and NCCLS M27-A2 Methods of Detection
Journal of clinical microbiology, 2005Co-Authors: M. J. Linares, Francisco Solís, Manuel CasalAbstract:A total of 104 Prototheca Wickerhamii isolates and two control strains were tested for susceptibility to voriconazole using the Sensititre YeastOne colorimetric antifungal plate and NCCLS reference method. Voriconazole was highly active against all isolates, with an MIC at which 90% of isolates were inhibited of
-
in vitro activity of voriconazole against Prototheca Wickerhamii comparative evaluation of sensititre and nccls m27 a2 methods of detection
Journal of Clinical Microbiology, 2005Co-Authors: M. J. Linares, Francisco Solís, Manuel CasalAbstract:A total of 104 Prototheca Wickerhamii isolates and two control strains were tested for susceptibility to voriconazole using the Sensititre YeastOne colorimetric antifungal plate and NCCLS reference method. Voriconazole was highly active against all isolates, with an MIC at which 90% of isolates were inhibited of <0.5 g/ml. Comparison of MICs obtained with the Sensititre product and the NCCLS method demonstrated agreement (100% 2 log2 dilutions) between the two methods. Voriconazole may offer an option for the treatment of Prototheca sp. infections, and its efficacy should be established through clinical experience. Species of the genus Prototheca (family Chlorellaceae) are ubiquitous, unicellular, achlorophyllic algae closely related to the green algae Chlorella spp. (12). Prototheca spp. have been isolated from tree sap, potato peel, seawater, lakes, marshes, streams, and pond mud, as well as from rivers and wastewater (2). The first description of human infection attributed to Prototheca spp. was reported by Davies et al. in 1964 (6). Subsequently there have been numerous reports of localized cutaneous and subcutaneous protothecosis (5, 10, 18) and, in rare instances, systemic disease (9, 17). The involvement of Prototheca spp. in human disease (3), in both immunocompetent and immunocompromised patients, has been reported with increasing frequency (19). Voriconazole is a monotriazole antifungal agent with activity against a broad spectrum of pathogenic fungi, among them Candida spp., including species displaying in vitro resistance to fluconazole, Cryptococcus neoformans and Aspergillus spp. (8). Our review of the literature did not reveal any studies that addressed the susceptibility of Prototheca spp. to voriconazole. This reports addresses the in vitro activity of voriconazole against strains of Prototheca Wickerhamii and compares the results obtained using two microdilution methods: the Sensititre YeastOne method and the National Committee for Clinical Laboratory Standards (NCCLS) reference broth microdilution method (15). One hundred four isolates of Prototheca Wickerhamii were selected for testing. Strains were isolated from various sources, the majority coming from patients’ fingernails, wastewater, and various culture collections. Cultures from collections were
-
in vitro activity of voriconazole against Prototheca Wickerhamii comparative evaluation of sensititre and nccls m27 a2 methods of detection
Journal of Clinical Microbiology, 2005Co-Authors: M. J. Linares, Francisco Solís, Manuel CasalAbstract:A total of 104 Prototheca Wickerhamii isolates and two control strains were tested for susceptibility to voriconazole using the Sensititre YeastOne colorimetric antifungal plate and NCCLS reference method. Voriconazole was highly active against all isolates, with an MIC at which 90% of isolates were inhibited of ≤0.5 μg/ml. Comparison of MICs obtained with the Sensititre product and the NCCLS method demonstrated agreement (100% ± 2 log2 dilutions) between the two methods. Voriconazole may offer an option for the treatment of Prototheca sp. infections, and its efficacy should be established through clinical experience.
-
In Vitro Activity of Voriconazole against Prototheca Wickerhamii: Comparative Evaluation of Sensititre and NCCLS M27-A2 Methods of Detection
2004Co-Authors: M. J. Linares, Manuel CasalAbstract:A total of 104 Prototheca Wickerhamii isolates and two control strains were tested for susceptibility to voriconazole using the Sensititre YeastOne colorimetric antifungal plate and NCCLS reference method. Voriconazole was highly active against all isolates, with an MIC at which 90 % of isolates were inhibited of<0.5 g/ml. Comparison of MICs obtained with the Sensititre product and the NCCLS method demonstrated agreement (100 % 2 log2 dilutions) between the two methods. Voriconazole may offer an option for the treatment of Prototheca sp. infections, and its efficacy should be established through clinical experience. Species of the genus Prototheca (family Chlorellaceae) are ubiquitous, unicellular, achlorophyllic algae closely related to the green algae Chlorella spp. (12). Prototheca spp. have been isolated from tree sap, potato peel, seawater, lakes, marshes, streams, and pond mud, as well as from rivers and wastewater (2). The first description of human infection attributed to Pro-totheca spp. was reported by Davies et al. in 1964 (6). Subse-quently there have been numerous reports of localized cuta-neous and subcutaneous protothecosis (5, 10, 18) and, in rar
M. J. Linares - One of the best experts on this subject based on the ideXlab platform.
-
In Vitro Activity of Voriconazole against Prototheca Wickerhamii: Comparative Evaluation of Sensititre and NCCLS M27-A2 Methods of Detection
Journal of clinical microbiology, 2005Co-Authors: M. J. Linares, Francisco Solís, Manuel CasalAbstract:A total of 104 Prototheca Wickerhamii isolates and two control strains were tested for susceptibility to voriconazole using the Sensititre YeastOne colorimetric antifungal plate and NCCLS reference method. Voriconazole was highly active against all isolates, with an MIC at which 90% of isolates were inhibited of
-
in vitro activity of voriconazole against Prototheca Wickerhamii comparative evaluation of sensititre and nccls m27 a2 methods of detection
Journal of Clinical Microbiology, 2005Co-Authors: M. J. Linares, Francisco Solís, Manuel CasalAbstract:A total of 104 Prototheca Wickerhamii isolates and two control strains were tested for susceptibility to voriconazole using the Sensititre YeastOne colorimetric antifungal plate and NCCLS reference method. Voriconazole was highly active against all isolates, with an MIC at which 90% of isolates were inhibited of <0.5 g/ml. Comparison of MICs obtained with the Sensititre product and the NCCLS method demonstrated agreement (100% 2 log2 dilutions) between the two methods. Voriconazole may offer an option for the treatment of Prototheca sp. infections, and its efficacy should be established through clinical experience. Species of the genus Prototheca (family Chlorellaceae) are ubiquitous, unicellular, achlorophyllic algae closely related to the green algae Chlorella spp. (12). Prototheca spp. have been isolated from tree sap, potato peel, seawater, lakes, marshes, streams, and pond mud, as well as from rivers and wastewater (2). The first description of human infection attributed to Prototheca spp. was reported by Davies et al. in 1964 (6). Subsequently there have been numerous reports of localized cutaneous and subcutaneous protothecosis (5, 10, 18) and, in rare instances, systemic disease (9, 17). The involvement of Prototheca spp. in human disease (3), in both immunocompetent and immunocompromised patients, has been reported with increasing frequency (19). Voriconazole is a monotriazole antifungal agent with activity against a broad spectrum of pathogenic fungi, among them Candida spp., including species displaying in vitro resistance to fluconazole, Cryptococcus neoformans and Aspergillus spp. (8). Our review of the literature did not reveal any studies that addressed the susceptibility of Prototheca spp. to voriconazole. This reports addresses the in vitro activity of voriconazole against strains of Prototheca Wickerhamii and compares the results obtained using two microdilution methods: the Sensititre YeastOne method and the National Committee for Clinical Laboratory Standards (NCCLS) reference broth microdilution method (15). One hundred four isolates of Prototheca Wickerhamii were selected for testing. Strains were isolated from various sources, the majority coming from patients’ fingernails, wastewater, and various culture collections. Cultures from collections were
-
in vitro activity of voriconazole against Prototheca Wickerhamii comparative evaluation of sensititre and nccls m27 a2 methods of detection
Journal of Clinical Microbiology, 2005Co-Authors: M. J. Linares, Francisco Solís, Manuel CasalAbstract:A total of 104 Prototheca Wickerhamii isolates and two control strains were tested for susceptibility to voriconazole using the Sensititre YeastOne colorimetric antifungal plate and NCCLS reference method. Voriconazole was highly active against all isolates, with an MIC at which 90% of isolates were inhibited of ≤0.5 μg/ml. Comparison of MICs obtained with the Sensititre product and the NCCLS method demonstrated agreement (100% ± 2 log2 dilutions) between the two methods. Voriconazole may offer an option for the treatment of Prototheca sp. infections, and its efficacy should be established through clinical experience.
-
In Vitro Activity of Voriconazole against Prototheca Wickerhamii: Comparative Evaluation of Sensititre and NCCLS M27-A2 Methods of Detection
2004Co-Authors: M. J. Linares, Manuel CasalAbstract:A total of 104 Prototheca Wickerhamii isolates and two control strains were tested for susceptibility to voriconazole using the Sensititre YeastOne colorimetric antifungal plate and NCCLS reference method. Voriconazole was highly active against all isolates, with an MIC at which 90 % of isolates were inhibited of<0.5 g/ml. Comparison of MICs obtained with the Sensititre product and the NCCLS method demonstrated agreement (100 % 2 log2 dilutions) between the two methods. Voriconazole may offer an option for the treatment of Prototheca sp. infections, and its efficacy should be established through clinical experience. Species of the genus Prototheca (family Chlorellaceae) are ubiquitous, unicellular, achlorophyllic algae closely related to the green algae Chlorella spp. (12). Prototheca spp. have been isolated from tree sap, potato peel, seawater, lakes, marshes, streams, and pond mud, as well as from rivers and wastewater (2). The first description of human infection attributed to Pro-totheca spp. was reported by Davies et al. in 1964 (6). Subse-quently there have been numerous reports of localized cuta-neous and subcutaneous protothecosis (5, 10, 18) and, in rar
Anil T Mangla - One of the best experts on this subject based on the ideXlab platform.
-
sterol c methyl transferase from Prototheca Wickerhamii mechanism sterol specificity and inhibition
Bioorganic & Medicinal Chemistry, 2000Co-Authors: Anil T ManglaAbstract:Abstract The membrane-bound sterol methyl transferase (SMT) enzyme from Prototheca Wickerhamii , a non-photosynthetic, yeast-like alga, was found to C -methylate appropriate Δ 24(25) -sterol acceptor molecules to Δ 25(27) -24β-methyl products stereoselectively. Incubation with pairs of substrates—[ 2 H 3 - methyl ]AdoMet and cycloartenol, and AdoMet and [27- 13 C]lanosterol—followed by 1 H and 13 C NMR analysis of the isotopically labeled products demonstrated the si -face (β-face attack) mechanism of C -methylation and the regiospecificity of Δ 25(27) -double bond formation from the pro- Z methyl group (C27) on lanosterol. The enzyme has a substrate preference for a sterol with a 3β-hydroxyl group, a planar nucleus and a side chain oriented into a ‘right-handed’ structure (20 R -chirality)—characteristic of the native substrate, cycloartenol. The apparent native molecular weight of the SMT was determined to be approximately 154,000, as measured by Superose 6 FPLC. A series of sterol analogues which contain heteroatoms substituted for C24 and C25 or related structural modifications, including steroidal alkaloids, havs been used to probe further the active site and mechanism of action of the SMT enzyme. Sterol side chains containing isoelectronic modifications of a positively charged moiety in the form of an ammonium group substituted for carbon at C25, C24, C23 or C22 are particularly potent non-competitive inhibitors ( K i for the most potent inhibitor tested, 25-azacycloartanol, was ca. 2 nM, four orders of magnitude less than the K m for cycloartenol of 28 μM), supporting the intermediacy of the 24-methyl C24(25)-carbenium ion intermediate. Ergosterol, but neither cholesterol nor sitosterol, was found to inhibit SMT activity ( K i =80 μM). The combination of results suggests that the interrelationships of substrate functional groups within the active center of a Δ 24(25) to Δ 25(27) 24β-methyl-SMT could be approximated thereby allowing the rational design of C -methylation inhibitors to be formulated and tested.
-
4,4,14α-trimethyl 9β,19-cyclo-5α-26-homocholesta-24,26-dien-3β-ol: a potent mechanism-based inactivator of Δ24(25)- to Δ25(27)-sterol methyl transferase
Bioorganic & medicinal chemistry letters, 1998Co-Authors: W. David Nes, Anil T ManglaAbstract:Abstract The title compound (4A) was synthesized and tested as a mechanism-based inactivator of the sterol methyl transferase (SMT) enzyme from Prototheca Wickerhamii . Using cycloartenol as substrate, 4A was found to exhibit time-dependent inactivation kinetics, generating a K i value of 30 μM and K inact value of 0.30 min −1 .
Francisco Solís - One of the best experts on this subject based on the ideXlab platform.
-
In Vitro Activity of Voriconazole against Prototheca Wickerhamii: Comparative Evaluation of Sensititre and NCCLS M27-A2 Methods of Detection
Journal of clinical microbiology, 2005Co-Authors: M. J. Linares, Francisco Solís, Manuel CasalAbstract:A total of 104 Prototheca Wickerhamii isolates and two control strains were tested for susceptibility to voriconazole using the Sensititre YeastOne colorimetric antifungal plate and NCCLS reference method. Voriconazole was highly active against all isolates, with an MIC at which 90% of isolates were inhibited of
-
in vitro activity of voriconazole against Prototheca Wickerhamii comparative evaluation of sensititre and nccls m27 a2 methods of detection
Journal of Clinical Microbiology, 2005Co-Authors: M. J. Linares, Francisco Solís, Manuel CasalAbstract:A total of 104 Prototheca Wickerhamii isolates and two control strains were tested for susceptibility to voriconazole using the Sensititre YeastOne colorimetric antifungal plate and NCCLS reference method. Voriconazole was highly active against all isolates, with an MIC at which 90% of isolates were inhibited of <0.5 g/ml. Comparison of MICs obtained with the Sensititre product and the NCCLS method demonstrated agreement (100% 2 log2 dilutions) between the two methods. Voriconazole may offer an option for the treatment of Prototheca sp. infections, and its efficacy should be established through clinical experience. Species of the genus Prototheca (family Chlorellaceae) are ubiquitous, unicellular, achlorophyllic algae closely related to the green algae Chlorella spp. (12). Prototheca spp. have been isolated from tree sap, potato peel, seawater, lakes, marshes, streams, and pond mud, as well as from rivers and wastewater (2). The first description of human infection attributed to Prototheca spp. was reported by Davies et al. in 1964 (6). Subsequently there have been numerous reports of localized cutaneous and subcutaneous protothecosis (5, 10, 18) and, in rare instances, systemic disease (9, 17). The involvement of Prototheca spp. in human disease (3), in both immunocompetent and immunocompromised patients, has been reported with increasing frequency (19). Voriconazole is a monotriazole antifungal agent with activity against a broad spectrum of pathogenic fungi, among them Candida spp., including species displaying in vitro resistance to fluconazole, Cryptococcus neoformans and Aspergillus spp. (8). Our review of the literature did not reveal any studies that addressed the susceptibility of Prototheca spp. to voriconazole. This reports addresses the in vitro activity of voriconazole against strains of Prototheca Wickerhamii and compares the results obtained using two microdilution methods: the Sensititre YeastOne method and the National Committee for Clinical Laboratory Standards (NCCLS) reference broth microdilution method (15). One hundred four isolates of Prototheca Wickerhamii were selected for testing. Strains were isolated from various sources, the majority coming from patients’ fingernails, wastewater, and various culture collections. Cultures from collections were
-
in vitro activity of voriconazole against Prototheca Wickerhamii comparative evaluation of sensititre and nccls m27 a2 methods of detection
Journal of Clinical Microbiology, 2005Co-Authors: M. J. Linares, Francisco Solís, Manuel CasalAbstract:A total of 104 Prototheca Wickerhamii isolates and two control strains were tested for susceptibility to voriconazole using the Sensititre YeastOne colorimetric antifungal plate and NCCLS reference method. Voriconazole was highly active against all isolates, with an MIC at which 90% of isolates were inhibited of ≤0.5 μg/ml. Comparison of MICs obtained with the Sensititre product and the NCCLS method demonstrated agreement (100% ± 2 log2 dilutions) between the two methods. Voriconazole may offer an option for the treatment of Prototheca sp. infections, and its efficacy should be established through clinical experience.
Deng-wei Chou - One of the best experts on this subject based on the ideXlab platform.
-
Prototheca Wickerhamii cutaneous and systemic infections.
The American journal of tropical medicine and hygiene, 2014Co-Authors: Deng-wei Chou, Kuo-mou Chung, Chao-tai LeeAbstract:Prototheca Wickerhamii, an environmental alga, rarely causes human infections. We present a case of Prototheca Wickerhamii cutaneous and systemic infections in an 85-year-old male with adrenal insufficiency. This organism was identified by morphological features and microbiological tests. The patient was successfully treated with ketoconazole.
-
Prototheca Wickerhamii cutaneous and systemic infections
American Journal of Tropical Medicine and Hygiene, 2014Co-Authors: Deng-wei Chou, Kuo-mou ChungAbstract:An 85-year-old male presented with a fever lasting for 2 days. He had a history of adrenal insufficiency with prednisolone use for 2 years. Pruritic erythematous maculopapules on his lower extremities appeared 1 year ago. On examination, he was febrile, tachycardic, and tachypneic. Multiple erythematous plaques were accompanied by papules, shallow ulcers, and crusts on his four limbs (Figure 1). Empirical piperacillin/tazobactam therapy was initiated. Blood cultures obtained on admission were positive after 3 days of incubation. Gram stain revealed spherical Gram-positive organisms of various sizes (Figure 2). A subculture on a blood agar plate showed milky white yeast-like colonies (Figure 3). A lactophenol cotton blue wet mount preparation disclosed characteristic endosporulating sporangia (Figure 4). The organisms isolated from both blood and cutaneous wound cultures were identified as Prototheca Wickerhamii using the API 20C identification system (bioMerieux, Marcy l’Etoile, France). Ketoconazole therapy was started on hospital Day 6. His clinical condition and cutaneous lesions improved with ketoconazole for a total of 4 weeks. Figure 1. Multiple erythematous plaques are accompanied by papules, shallow ulcers, and crusts on his right upper limb and left lower limb. Figure 2. Gram stain of blood culture reveals spherical Gram-positive organisms of various sizes resembling yeast. Magnification, ×1,000. Figure 3. Milky white yeast-like colonies are observed on blood agar plate after incubation at 35°C for 3 days. Figure 4. Wet-mount preparation with lactophenol cotton blue discloses spherical sporangia containing multiple endospores with symmetrical arrangement. Magnification, ×1,000. Prototheca Wickerhamii is an achlorophyllic alga and is ubiquitous in nature, which can cause human infections. The definite diagnosis usually depends on morphological identification of the organisms in wet slide preparations of cultures and/or direct identification in tissue specimens.1
-
Images in Clinical Tropical Medicine Prototheca Wickerhamii Cutaneous and Systemic Infections
2014Co-Authors: Deng-wei Chou, Kuo-mou Chung, Chao-tai LeeAbstract:Prototheca Wickerhamii, an environmental alga, rarely causes human infections. We present a case of Prototheca Wickerhamii cutaneous and systemic infections in an 85-year-old male with adrenal insufficiency. This organism was identified by morphological features and microbiological tests. The patient was successfully treated with ketoconazole.
